Recent Articles

Taysha reports financial results as well as updates on their pediatric and adult clinical trials.

Neurogene announced initial safety and tolerability data from its Rett gene therapy clinical. NGN-401 was generally well-tolerated by all three patients dosed, with follow-up of approximately 9, 6 and 3 months post-dosing. These data were presented during the American Society of Gene and Cell ...

Taysha announced the FDA has granted RMAT designation to TSHA-102. Companies receiving RMAT designation can benefit from increased interactions with the FDA with the goal of expediting drug development.

UMASS Chan Medical School announces the $2.3 million award from RSRT to develop genetic medicines for Rett syndrome.